Inovio Pharmaceuticals, Inc. (NASDAQ:INO – Get Free Report)’s share price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.27 and traded as high as $1.37. Inovio Pharmaceuticals shares last traded at $1.27, with a volume of 5,623,595 shares traded.
Analyst Upgrades and Downgrades
A number of research firms have commented on INO. Weiss Ratings lowered Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 13th. Zacks Research raised shares of Inovio Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, August 12th. Piper Sandler reissued an “overweight” rating and issued a $4.00 price target on shares of Inovio Pharmaceuticals in a research note on Monday, August 3rd. Wall Street Zen raised shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Inovio Pharmaceuticals in a report on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Inovio Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $3.17.
View Our Latest Stock Report on INO
Inovio Pharmaceuticals Trading Up 0.4%
Inovio Pharmaceuticals (NASDAQ:INO – Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.15. Research analysts anticipate that Inovio Pharmaceuticals, Inc. will post -0.72 earnings per share for the current year.
Institutional Investors Weigh In On Inovio Pharmaceuticals
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Focus Partners Wealth purchased a new stake in Inovio Pharmaceuticals in the 3rd quarter valued at $33,000. Headlands Technologies LLC acquired a new position in Inovio Pharmaceuticals in the 2nd quarter valued at about $33,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Inovio Pharmaceuticals by 39.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 5,894 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in Inovio Pharmaceuticals by 752.9% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 20,572 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 18,160 shares in the last quarter. Finally, Raymond James Financial Inc. grew its position in shares of Inovio Pharmaceuticals by 4,396.0% during the third quarter. Raymond James Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 16,309 shares in the last quarter. 26.79% of the stock is currently owned by institutional investors and hedge funds.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.
Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.
See Also
- Five stocks we like better than Inovio Pharmaceuticals
- Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
- J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It
- Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real?
- GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
